MRKR Logo

Marker Therapeutics, Inc. (MRKR) 

NASDAQ
Market Cap
$35.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
626 of 776
Rank in Industry
339 of 433

Largest Insider Buys in Sector

MRKR Stock Price History Chart

MRKR Stock Performance

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies …

Insider Activity of Marker Therapeutics, Inc.

Over the last 12 months, insiders at Marker Therapeutics, Inc. have bought $0 and sold $0 worth of Marker Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Marker Therapeutics, Inc. have bought $106.52M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $24,098 was made by Wasserman Frederick Gerald (director) on 2021‑05‑18.

List of Insider Buy and Sell Transactions, Marker Therapeutics, Inc.

2021-05-18Purchasedirector
10,000
0.0119%
$2.41$24,098-43.03%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchase10 percent owner
5.71M
9.5207%
$1.75$10M-4.30%
2021-03-16Purchasedirector
1.71M
2.8562%
$1.75$3M-4.30%
2021-03-16Purchasedirector
1.14M
1.9041%
$1.75$2M-4.30%
2021-03-16PurchaseChief Development Officer
571,428
0.9521%
$1.75$999,999-4.30%
2021-03-16PurchasePresident and CEO
142,857
0.238%
$1.75$250,000-4.30%
2021-03-16Purchasedirector
14,285
0.238%
$17.50$249,988-4.30%
2019-08-14PurchasePresident and CEO
10,000
0.0219%
$4.62$46,200-41.13%
2018-05-14Purchase10 percent owner
2.6M
17.57%
$2.40$6.24M+127.00%
2011-03-23SalePresident and CFO
320,000
0.4732%
$0.12$38,4000.00%

Insider Historical Profitability

<0.0001%
MAKOWER JOSHUA10 percent owner
10714285
120.0791%
$4.0310<0.0001%
SANDELL SCOTT D10 percent owner
10714285
120.0791%
$4.0310<0.0001%
BASKETT FOREST10 percent owner
10714285
120.0791%
$4.0310<0.0001%
Walker Paul Edward10 percent owner
10714285
120.0791%
$4.0310<0.0001%
Sonsini Peter W.10 percent owner
10714285
120.0791%
$4.0310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$4.61M12.011.07M0%+$00.02
Aisling Capital Management LP$1.35M3.52314,2860%+$00.46
The Vanguard Group$1M2.62233,231+3.63%+$35,148.22<0.0001
Ar Asset Management Inc$304,000.000.7970,7000%+$00.08
Geode Capital Management$288,401.000.7567,053+11.67%+$30,133.44<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.